European Investment Bank

Sidekick is a patient-centric digital care platform designed to enhance the management and prevention of chronic and lifestyle-related conditions. By integrating evidence-based clinical approaches with behavioral economics and gamification, Sidekick's platform empowers patients to engage in personalized wellness activities. The platform facilitates multi-chronic condition management through gamified health engagement methods, health screening, and analytics, allowing users to connect with clinicians and gain valuable data insights. Sidekick collaborates with international pharmaceutical companies, payers, and healthcare providers to prioritize patient needs and improve the overall healthcare experience, making it more accessible and efficient.

Universal Diagnostics, S.L. is a biomedicine company based in Seville, Spain, with an additional office in San Francisco, California. Founded in 2012, the company focuses on developing blood-based tests for the early detection of various cancers, including colorectal, lung, liver, pancreatic, and gastric cancers. Its diagnostic platform utilizes proprietary methylation marker panels, allowing for minimally invasive testing that can be performed using standard laboratory equipment. The first test developed by Universal Diagnostics is aimed at colorectal cancer screening, identifying individuals who may require further examination through colonoscopy. The company emphasizes the importance of early detection, as this can significantly improve treatment options and survival rates. To advance its research and development efforts, Universal Diagnostics collaborates with international research institutions, hospitals, universities, and biobanks worldwide.

Amadix is a biotechnology company focused on the development and commercialization of innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company aims to enhance early cancer detection through non-invasive methods, significantly improving patient outcomes and reducing the complications associated with traditional invasive procedures like tumor biopsies. Amadix's flagship product, Colofast, is a non-invasive blood test designed for the screening of colorectal cancer and advanced adenoma diagnosis, targeting the high mortality rate associated with this disease. The company is committed to validating its products through international multicenter studies to ensure clinical efficacy before global commercialization. The team at Amadix comprises experienced professionals with extensive backgrounds in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by an independent board of advisors with deep expertise in oncology and diagnostics, guiding the company's strategic and commercial efforts.

NVision Imaging Technologies GmbH, founded in 2015 and based in Ulm, Germany, specializes in the development and commercialization of innovative imaging and sensing applications grounded in quantum physics. The company has created a platform that polarizes natural metabolites, enabling their use as agents for imaging tumor metabolism through magnetic resonance imaging (MRI). This technology transforms standard magnetic resonance spectrometers into tools capable of assessing human metabolism, thereby enhancing the precision of cancer diagnostics and facilitating real-time monitoring of patient responses to therapy. By leveraging advances in quantum physics, NVision aims to make significant strides in the medical imaging and diagnostics sector.

MEDZ’s vision is to maintain its leading position as a distinguished State partner in the implementation of sectoral strategies* to build a competitive Morocco.

Smart Reporting GmbH is a Munich-based company that specializes in providing a digital health solution for structured medical reporting, particularly in the fields of radiology and pathology. Established in 2014, the company offers an online platform that enables radiologists to generate high-quality medical reports through intelligent software that adheres to guideline-compliant criteria. The platform facilitates the creation of report templates, automatic text suggestions, and integration with hospital systems, thereby enhancing the efficiency and quality of medical reporting. Additionally, Smart Reporting provides tools for hospitals and practices to implement reporting standards, optimize templates, and ensure consistent report appearance across various physicians. The company also supports medical registries and clinical studies with solutions for structured reporting, data collection, and multilingual capabilities, all aimed at improving communication and quality assurance in medical documentation.

GeNeuro is a biotechnology company based in Plan-Les-Ouates, Switzerland, specializing in the development of therapeutic drugs for diseases linked to pathogenic proteins originating from human endogenous retroviruses. The company primarily targets nervous system disorders, including multiple sclerosis and schizophrenia. Its lead product, GNbAC1, is a therapeutic monoclonal antibody designed to treat multiple sclerosis, while temelimab is another candidate that neutralizes a pathogenic protein from the HERV-W family. Additionally, GeNeuro is engaged in developing diagnostic tests to measure multiple sclerosis-associated retrovirus-ENV proteins in patients. Founded in 2006, the company is committed to addressing the underlying factors that drive the progression of neurodegenerative and autoimmune diseases.

Icosagen Group is a contract research provider and technology developer based in Tartumaa, Estonia, serving the biopharmaceutical and biotechnology sectors, as well as academic institutions. The company specializes in high-end biotechnology services, including protein and antibody production, as well as virus-like particle (VLP) production. Its product offerings encompass antibodies, proteins, ELISA kits, transfection reagents, and DNA/RNA isolation tools. Additionally, Icosagen provides quality control services, such as food microbiology testing and allergen testing. The company is involved in various international and national research initiatives, contributing to projects like INTENSO, MAARS, and EURIPRED. Icosagen's proprietary QMCF Technology allows for the stable expression of recombinant proteins and antibodies in mammalian cells, facilitating the development of cell-based assays for screening purposes. The Icosagen Group comprises three entities: the parent company Icosagen AS and its subsidiaries, Icosagen Cell Factory Ltd and IcoPark Ltd.

numares AG is a German company specializing in the development and marketing of software-based test systems for clinical diagnostics and life science research. Founded in 2004 and based in Regensburg, the company utilizes nuclear magnetic resonance (NMR) spectroscopy and machine learning to analyze metabolomic networks. Its AXINON in vitro diagnostic system produces numeric spectra that provide critical information regarding patients' disease statuses, particularly in the fields of cardiovascular diseases, nephrology, oncology, and neurology. By employing magnetic group signaling (MGS) technology, numares AG offers a reliable, efficient, and cost-effective solution for NMR-based diagnostics, positioning itself as a leader in commercial NMR analytics in Europe while providing expert support to its customers.

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system for early-stage sepsis. The company's approach focuses on rapidly identifying pathogens and delivering antibiogram results within hours. By utilizing artificial intelligence, DeepUll is able to determine the infective agent and provide insights into antimicrobial susceptibility, which helps reduce unnecessary antibiotic use. This system not only enables quick detection of pathogens and antibiotic resistance without the need for prior cultivation but also allows healthcare providers to assess a patient's immunological and functional status. Consequently, DeepUll's technology empowers doctors to predict the onset and progression of sepsis, facilitating timely clinical interventions even before symptoms manifest.

Demant is a Denmark-based company that specializes in hearing healthcare, encompassing a comprehensive range of products and services. It manufactures and distributes hearing devices, hearing implants, and diagnostic instruments, along with offering professional hearing care. This unique position in the market allows Demant to leverage significant synergies and create new opportunities for growth. The company generates over 80% of its sales from North America and Europe, highlighting its strong presence in these key markets.

CompuGroup Medical provides a range of electronic health solutions designed to enhance the efficiency and effectiveness of healthcare providers. The company operates through four main segments: Ambulatory Information Systems, Pharmacy Information Systems, Hospital Information Systems, and Consumer and Health Management Information Systems. The Ambulatory Information Systems segment is the largest, offering practice management software and electronic medical record solutions tailored for physician practices and clinics. The Pharmacy Information Systems segment delivers clinical, administrative, and financial software for retail pharmacies. Additionally, the Hospital Information Systems segment focuses on solutions for inpatient centers, while the Consumer and Health Management Information Systems segment addresses the needs of patients and healthcare consumers. CompuGroup Medical's comprehensive offerings support a wide array of healthcare stakeholders, including doctors, clinics, hospitals, and pharmaceutical companies, facilitating improved workflows, diagnoses, and therapies on a global scale.

POCARED Diagnostics Ltd. is a medical device company based in Rehovot, Israel, specializing in in-vitro diagnostics. Founded in 2004, the company has developed a next-generation microbiology platform known as the P-1000, which offers a fully automated and reagent-free solution for real-time analysis of human fluids and specimens. This innovative platform enables rapid detection, identification, and antibiotic sensitivity assessment of pathogenic bacteria and yeast, significantly reducing the time required for result reporting from several days to just a few minutes. By providing multi-source detection and quantification, POCARED Diagnostics aims to enhance the accuracy and efficiency of infectious disease diagnosis, making it easier for healthcare providers to make informed decisions. As of September 2020, POCARED operates as a subsidiary of Naftali Investments Ltd.

Diadem is a biotechnology company that focuses on developing a diagnostic platform to predict Alzheimer's disease. Utilizing a proprietary blood-based test, the company targets a specific conformation of the p53 protein through a unique antibody. This innovative approach allows for early predictions, monitoring, and diagnosis of Alzheimer's, ultimately facilitating more effective drug development. By providing accurate and timely information, Diadem aims to enhance the treatment options available for Alzheimer's patients while ensuring that these solutions are cost-effective.

miDiagnostics is a Belgian company focused on creating innovative, chip-based technology for self-administered blood analysis. The company is developing a new generation of disposable tests that require only small drops of blood, allowing for the detection of various biomarkers, including cells, proteins, nucleic acids, and small molecules. Their technology integrates a nanofluidic processor on a chip with a compact reader, facilitating lab-quality diagnostics from easy-to-access samples like finger-prick blood or nasal swabs. This approach enables both patients and clinicians to conduct rapid diagnostics conveniently and efficiently, regardless of location.

Cape Bio Pharms is a biotech company that develops a plant-based platform for the production of proteins for rapid diagnostic test kits and biomedical research. The company's plans are designed to commercialize biotech for the production of recombinant proteins in tobacco, providing life scientists with a diverse range of premium, moderate, and custom plant-made recombinant proteins with reproducible results.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, specializing in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures in the fields of cardiology, interventional radiology, and vascular surgery. Its primary product is a large-bore percutaneous closure device that employs an absorbable patch to effectively close large arteriotomies following transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical is dedicated to advancing medical solutions that enhance patient outcomes in vascular access procedures.

Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

Indivumed was founded in Hamburg, Germany in 2002 with one main driver – the individualization of cancer therapy through the generation, characterization, and analysis of biologic samples from human cancer patients. Since then, the company has expanded globally, with a subsidiary in the USA, partnerships with leading cancer clinics in Europe, the US and Asia and more than 50 oncology practices located in Germany, and, finally, more than 100 biopharma industry partners – and a global reputation for product and service quality.

EGYM is a global fitness technology company that specializes in providing intelligent workout solutions for fitness and health facilities. The company offers a comprehensive platform that integrates connected gym equipment and software, enabling operators to enhance the workout experience for their members. EGYM's offerings include a B2B corporate fitness subscription solution tailored for employers, as well as personalized, data-driven fitness experiences for users. This approach supports individuals in achieving their fitness goals, whether related to muscle gain, performance, or rehabilitation. EGYM's commitment to member success is reflected in its belief that the success of gym operators is intrinsically linked to the progress of their members towards improved physical and mental wellness.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

NewIcon Oy is a health technology company established in 2007, specializing in pharmacy automation systems. As a market leader in Finland, the company has successfully implemented its automated medication dispensing solutions in over 100 pharmacies and hospitals across multiple countries, including Denmark, Russia, Israel, Iran, and China. With a workforce of approximately 70 employees, NewIcon Oy generates a turnover exceeding € 7 million. The company is committed to quality, operating under a certified ISO 9001 quality management system, and focuses on using robotics and advanced software to enhance the efficiency and safety of medication distribution, allowing healthcare providers to prioritize patient care.